Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC

NCT01186861 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01186861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01186861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Erlotinib Plus Placebo in Patients With Nonprogression Following Four Cycles of 1st-line Platinum-based Chemotherapy for Advanced NSCLC
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2011
Completion date
March 11, 2015
Enrollment
205 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc) with nonprogression following 4 cycles of platinum-based chemotherapy